GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for slowing Alzheimer’s — a disease with few treatment options.

Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity--announced that Mr. Jesper Høiland has been ...

The stock of telemedicine provider Hims & Hers has been under intense pressure, shedding approximately 38% of its value since ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, ...

Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...

Novo Nordisk’s closest rival is Eli Lilly, whose GLP-1 drugs have also posted strong demand. A softer read on IRA discounts ...

Marketers are positioning weight-loss shots as cosmetic elixirs for anyone who wants to lose a few pounds. Doctors warn that ...